Emmaus Life SciencesEMMA -7.26% 3-Year ROIIC % is -30.21 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 1,325 Biotechnology companies, Emmaus Life Sciences ranks worse than 60.6% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Emmaus Life Sciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -30.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Emmaus Life Sciences's 3-Year ROIIC % or its related term are showing as below:
EMMA's 3-Year ROIIC % is ranked worse than 60.6% of 1325
companies
in the Biotechnology industry
Industry Median: -4.44
vs EMMA: -30.21
Emmaus Life Sciences (OTCPK:EMMA) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Emmaus Life Sciences 3-Year ROIIC % Related Terms
Emmaus Life Sciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs PTIX, BZYR, RMTG: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's 3-Year ROIIC % falls into.
Emmaus Life Sciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 0.231 (Dec. 2025) - -6.586 (Dec. 2022) )
/
( 60.147 (Dec. 2025) - 82.71 (Dec. 2022) )
=
6.817
/
-22.563
=
-30.21%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Emmaus Life Sciences (EMMA) has a 3-Year ROIIC % of -30.21 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #803 out of 1325 companies in the Biotechnology industry, placing it in the top 60.6%.
Is Emmaus Life Sciences' 3-Year ROIIC % too high?
Emmaus Life Sciences' current 3-Year ROIIC % is -30.21. Based on the distribution chart, Emmaus Life Sciences ranks #803 out of 1325 companies in the Biotechnology industry, which is below the industry midpoint.
How does Emmaus Life Sciences' 3-Year ROIIC % compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #803 out of 1325 companies for 3-Year ROIIC %. This places Emmaus Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current 3-Year ROIIC % is -30.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 8.5% above its estimated fair value. The current 3-Year ROIIC % is -30.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 3-Year ROIIC % is -30.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 